Cargando…
The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors
The FDA-approved anti-DNA virus agent cidofovir (CDV) is being evaluated in phase II/III clinical trials for the treatment of human papillomavirus (HPV)-associated tumors. However, previous observations had shown that CDV also inhibits the growth of vascular tumors induced by fibroblast growth facto...
Autores principales: | Liekens, Sandra, Noppen, Sam, Gijsbers, Sofie, Sienaert, Rebecca, Ronca, Roberto, Tobia, Chiara, Presta, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467104/ https://www.ncbi.nlm.nih.gov/pubmed/25609197 |
Ejemplares similares
-
Cidofovir for the Treatment of Molluscum Contagiosum Virus
por: De Clercq, Erik
Publicado: (2022) -
Isolation and characterization of cidofovir resistant vaccinia viruses
por: Becker, Marie N, et al.
Publicado: (2008) -
The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach
por: Rezzola, Sara, et al.
Publicado: (2019) -
Treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir
por: Enescu, Christina D., et al.
Publicado: (2021) -
Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir
por: Quenelle, Debra C, et al.
Publicado: (2004)